厄贝沙坦治疗糖尿病肾病的临床研究

目的探讨厄贝沙坦治疗糖尿病肾病的临床效果。方法选取本院2010年10月～2012年7月糖尿病肾病患者39例,随机分为两组,服用马来酸氨氯地平患者19例为对照组,服用厄贝沙坦患者20例为观察组,治疗3个月,比较两组患者的临床指征。结果治疗前后,对照组与观察组收缩压、舒张压、空腹血糖变化不显著,差异无统计学意义（P〉0.05）。治疗后,对照组与观察组24h尿蛋白均明显下降,观察组24h尿蛋白明显低于对照组,差异均有统计学意义（P〈0.05）。结论厄贝沙坦是治疗糖尿病肾病的有效方法,可明显改善患者的临床病症,减少尿蛋白,具有显著的临床疗效。

Clinical research of irbesartan in treatment for diabetic nephropathy

Objective To investigate the clinical effect of irbesartan in treatment for diabetic nephropathy. Methods Thirty nine patients with diabetic nephropathy were selected in hospital from October 2010 to July 2012, who were randomly divided into two groups, 19 patients used amlodipine maleate as control group, 20 patients used irbesartan as observation group. After treatment for 3 months, clinical indications were compared between two groups. Results Be- fore and after treatment, systolic blood pressure, diastolic blood pressure, fasting blood glucose in control group and observation group had no significant change, the difference was not statistically significant （P 〉 0.05）. After treatment, 24 h urinary protein decreased significantly in control group and observation group, 24 h urinary protein in observation group was significantly lower than control group, the difference was statistically significant （P 〈 0.05）. Conclusion Irbesartan is an effective method in treatment for diabetic nephropathy, which can obviously improve clinical condition of patients. That can decrease urine protein and has obvious clinical effect.